Overview

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Status:
RECRUITING

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate \[ORR; Cohorts 1,2, 4,and 5\] and disease control rate \[DCR; Cohort 3\]) in patients with advanced or metastatic gastrointestinal (GI) tumors. Cohorts 1-4 are not randomized; however, Cohort 5 is comprised of two treatment arms to which patients are randomized in a 1:1 ratio.

Phase:

PHASE1

Details

Lead Sponsor:

Oncolytics Biotech

Collaborators:

AIO-Studien-gGmbH
Crolll Gmbh

Treatments:

130-nm albumin-bound paclitaxel
Albumin-Bound Paclitaxel
atezolizumab
Gemcitabine
reolysin
trifluridine tipiracil drug combination